Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 101–200 of 910
Glucocorticoids: Complications to Anticipate and Prevent
Gensler, L. S. (2013) · The Neurohospitalist · doi:10.1177/1941874412458678 · Cited by 100
Khandelwal, S., & Lane, N. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.009 · Cited by 118
Langdahl, B. L., Rajzbaum, G., Jakob, F. J., Karras, D., Ljunggren, Ö., Lems, W. F., Fahrleitner‐Pammer, A., Walsh, J. B., Barker, C., Kutahov, A., et al. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9299-6 · Cited by 99
Self-citationMcClune, B. L., Polgreen, L. E., Burmeister, L. A., Blaes, A. H., Mulrooney, D. A., Burns, L. J., & Majhail, N. S. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.198 · Cited by 98
Approach to the patient with secondary osteoporosis
Hofbauer, L. C., Hamann, C., & Ebeling, P. R. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0015 · Cited by 95
Raterman, H. G., & Lems, W. F. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00714-4 · Cited by 100
MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis
CANALIS, E. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0920 · Cited by 104
Osteoanabolic and dual action drugs
Tabacco, G., & Bilezikian, J. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13766 · Cited by 96
Glucocorticoid-induced osteoporosis update
Adami, G., & Saag, K. G. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000608 · Cited by 95
Self-citationBad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes
Gado, M., Baschant, U., Hofbauer, L. C., & Henneicke, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.835720 · Cited by 108
Thiazolidinedione‐induced skeletal fragility – mechanisms and implications
Grey, A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00931.x · Cited by 90
Hui, J. Y., Choi, J. W. J., Mount, D. B., Zhu, Y., Zhang, Y., & Choi, H. K. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3769 · Cited by 90
Senn, C., Günther, B., Popp, A. W., Perrelet, R., Hans, D. B., & Lippuner, K. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2703-8 · Cited by 91
Saag, K. G., Agnusdei, D., Hans, D. B., Kohlmeier, L., Krohn, K., Leib, E. S., Maclaughlin, E. J., Alam, J., Simonelli, C., Taylor, K. A., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39726 · Cited by 97
Self-citationWatanabe, A., Yoneyama, S., Nakajima, M., Sato, N., Takao-Kawabata, R., Isogai, Y., Sakurai-Tanikawa, A., Higuchi, K., Shimoi, A., Yamatoya, H., et al. (2012) · The Journal of Toxicological Sciences · doi:10.2131/jts.37.617 · Cited by 88
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis
Eriksen, E. F., Keaveny, T. M., Gallagher, E. R., & Krege, J. H. (2014) · Bone · doi:10.1016/j.bone.2014.07.014 · Cited by 117
Management of Glucocorticoid-Induced Osteoporosis
Rizzoli, R., Adachi, J. D., Cooper, C. C., Dere, W. H., Devogelaer, J. P., Díez‐Pérez, A., Kanis, J. А., Laslop, A., Mitlak, B., Papapoulos, S. E., et al. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9630-5 · Cited by 89
From bone biology to clinical outcome: state of the art and future perspectives
Schett, G. A., Saag, K. G., & Bijlsma, J. W. J. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135061 · Cited by 86
Self-citationTeriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study
Cohen, A., Stein, E. M., Recker, R. R., Lappe, J. M., Dempster, D. W., Zhou, H., Cremers, S., McMahon, D. J., Nickolas, T. L., Müller, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1172 · Cited by 87
Self-citationOne-Pot Peptide Ligation–Desulfurization at Glutamate
Cergol, K. M., Thompson, R. E., Malins, L. R., Turner, P., & Payne, R. J. (2013) · Organic Letters · doi:10.1021/ol403288n · Cited by 85
The future of osteoporosis treatment – a research update
Lippuner, K. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13624 · Cited by 93
Effect of Bifidobacterium on osteoclasts: TNF-α/NF-κB inflammatory signal pathway-mediated mechanism
Wu, Y., Yang, Y., Wang, L., Chen, Y., Han, X., Sun, L., Chen, H., & Chen, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1109296 · Cited by 96
EUROFORS Study Group, Blumsohn, A., Marin, F., Nickelsen, T., Brixen, K., Sigurdsson, G., González de la Vera, J., Boonen, S., Liu-Léage, S., Barker, C., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1379-y · Cited by 80
Self-citationGeorgiou, K. R., Hui, S. K., & Xian, C. J. (2012) · Europe PMC (PubMed Central) · Cited by 90
Glucocorticoids and osteocyte autophagy
Yao, W., Dai, W., Jiang, J. X., & Lane, N. E. (2013) · Bone · doi:10.1016/j.bone.2013.01.034 · Cited by 78
Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Pereira, R. M. R., Carvalho, J. F. D., Paula, A. P., Zerbini, C., Domiciano, D. S., Gonçalves, H., Danowski, J. S., Marques Neto, J. F., Mendonça, L. M. C., Bezerra, M. C., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400009 · Cited by 80
Endocrine Aspects of Duchenne Muscular Dystrophy
Bianchi, M. L., Biggar, D., Bushby, K. M. D., Rogol, A. D., Rutter, M. M., & Tseng, B. S. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.02.006 · Cited by 80
Osteoporosis in Chronic Obstructive Pulmonary Disease
Sarkar, M. S., Bhardwaj, R., Madabhavi, I., & Khatana, J. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s22803 · Cited by 98
Mok, C. C., Ying, K. Y., To, C. H., Ho, L. Y., Yu, K. L., Lee, H. K., & M., K. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143453 · Cited by 78
Autophagy as a target for glucocorticoid-induced osteoporosis therapy
Shen, G., Ren, H. J., Shang, Q., Qiu, T., Yu, X., Zhang, Z., Huang, J., Zhao, W., Zhang, Y., Liang, D., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2776-1 · Cited by 79
Glucocorticoid-induced osteoporosis in rheumatic diseases
Pereira, R. M. R., de Carvalho, J. F., & CANALIS, E. M. (2010) · Clinics · doi:10.1590/s1807-59322010001100024 · Cited by 77
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 104
Vascular Calcification and Renal Bone Disorders
Lu, K., Wu, C., Yen, J.-F., & Liu, W.-C. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/637065 · Cited by 81
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases
Buttgereit, F., Palmowski, A., Bond, M., Adami, G., & Dejaco, C. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01120-w · Cited by 85
Osteoporosis and gastrointestinal disease.
Katz, S., & Weinerman, S. A. (2010) · PubMed · Cited by 94
Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide
Pleiner-Duxneuner, J., Zwettler, E., Paschalis, E. P., Roschger, P., Nell-Duxneuner, V., & Klaushofer, K. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9218-x · Cited by 78
Anabolic action of parathyroid hormone regulated by the β 2 -adrenergic receptor
Hanyu, R., Wehbi, V. L., Hayata, T., Moriya, S., Feinstein, T. N., Ezura, Y., Nagao, M., Saita, Y., Hemmi, H., Notomi, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109036109 · Cited by 70
Recognizing and treating secondary osteoporosis
Walker-Bone, K. E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.93 · Cited by 78
Chronic kidney disease and the skeleton
Miller, P. D. (2014) · Bone Research · doi:10.1038/boneres.2014.44 · Cited by 76
CAREY, J. J., & Delaney, M. F. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9064-4 · Cited by 86
Hamann, C., Picke, A.-K., Campbell, G. M., Balyura, M., Rauner, M., Bernhardt, R., Huber, G., Morlock, M. M., Günther, K.-P., Bornstein, S. R., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1960 · Cited by 68
Management of Osteoporosis in Men: A Narrative Review
Vescini, F., Chiodini, I., Falchetti, A., Palermo, A., Salcuni, A. S., Bonadonna, S., Geronimo, V. D., Cesareo, R., Giovanelli, L., Brigo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413640 · Cited by 82
Glucocorticoid-induced osteoporosis: novel concepts and clinical implications
Hofbauer, L. C., Compston, J. E., Saag, K. G., Rauner, M., & Tsourdi, E. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00251-7 · Cited by 90
Self-citationGoal-directed treatment of osteoporosis in Europe
Kanis, J. А., McCloskey, E. V., Branco, J., Brandi, M. L., Dennison, E. M., Devogelaer, J.-P., Ferrari, S., Kaufman, J., Papapoulos, S. E., Reginster, J., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2787-1 · Cited by 72
Lehman, R. A., Dmitriev, A. E., Cardoso, M. J., Helgeson, M. D., Christensen, C. L., Raymond, J. W., Eckel, T. T., & Riew, K. D. (2010) · Spine · doi:10.1097/brs.0b013e3181b71a96 · Cited by 67
Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
Bisphosphonate Fractures as a Cause of Painful Total Hip Arthroplasty
Curtin, B. M., & Fehring, T. K. (2011) · Orthopedics · doi:10.3928/01477447-20111021-36 · Cited by 115
Al‐Saleh, Y., Sulimani, R. A., Sabico, S., Raef, H., Fouda, M. A., Alshahrani, F., Shaker, M., Wahabi, B. A., Sadat‐Ali, M., Rayes, H. A., et al. (2015) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2015.1 · Cited by 68
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
Raterman, H. G., Bultink, I. E. M., & Lems, W. F. (2019) · Drugs · doi:10.1007/s40265-019-01145-6 · Cited by 65
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 90
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
Stepan, J. J., Burr, D. B., Li, J., Ma, Y. L., Petto, H., Sipos, A., Dobnig, H., Fahrleitner‐Pammer, A., Michalská, D., & Pavo, I. J. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1168-7 · Cited by 63
Anabolic therapy for osteoporosis: update on efficacy and safety
Bandeira, L., & Lewiecki, E. M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000566 · Cited by 74
Glucocorticoid-induced osteoporosis: treatment update and review
Fraser, L.-A., & Adachi, J. D. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09343729 · Cited by 73
Pharmacological management of osteogenesis
Nardone, V., D’Asta, F., & Brandi, M. L. (2014) · Clinics · doi:10.6061/clinics/2014(06)12 · Cited by 67
Osteoporosis in premenopausal women
Langdahl, B. L. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000400 · Cited by 69
New therapeutic targets for osteoporosis
Anagnostis, P. G., Gkekas, N. K., Potoupnis, M. E., Kenanidis, E. I., Tsiridis, E. E., & Goulis, D. G. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.11.010 · Cited by 67
Barnabe, C. C. M., & Hanley, D. A. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.04.004 · Cited by 61
Prevention of glucocorticoid morbidity in giant cell arteritis
Buttgereit, F., Matteson, E. L., Dejaco, C., & Dasgupta, B. (2017) · Rheumatology · doi:10.1093/rheumatology/kex459 · Cited by 62
Safety of parathyroid hormone for the treatment of osteoporosis
Miller, P. D. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0003-y · Cited by 60
Safety issues and adverse reactions with osteoporosis management
Rossini, M., Adami, G., Adami, S., Viapiana, O., & Gatti, D. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1136287 · Cited by 71
Peptide-based delivery to bone
Aoki, K., Alles, N., Soysa, N. S., & Ohya, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.017 · Cited by 59
Nishiyama, K. K., Cohen, A., Young, P., Wang, J., Lappe, J. M., Guo, X.-D. E., Dempster, D. W., Recker, R. R., & Shane, E. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1041 · Cited by 60
Self-citationDiagnosis and Management of Asthma in Older Adults
Chotirmall, S. H., Watts, M., Branagan, P., Donegan, C. F., Moore, A. R., & McElvaney, N. G. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02216.x · Cited by 66
Secondary osteoporosis in patients with an osteoporotic fracture
Kok, C., & Sambrook, P. N. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.006 · Cited by 57
Devogelaer, J., Adler, R. A., Recknor, C. P., See, K., Warner, M. R., Wong, M., & Krohn, K. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090411 · Cited by 61
Treatment Sequence for Osteoporosis
Cosman, F., Langdahl, B. L., & Leder, B. Z. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.01.014 · Cited by 68
Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton
Dubrovsky, A., Lim, M. J., & Lane, N. E. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0401-9 · Cited by 61
Leder, B. Z., Mitlak, B., Hu, M., Hattersley, G., & Bockman, R. S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz162 · Cited by 67
Should bisphosphonates be used for long‐term treatment of glucocorticoid‐induced osteoporosis?
Teitelbaum, S. L., Seton, M., & Saag, K. G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30135 · Cited by 56
Self-citationAdvanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis
Kalpakcioglu, B. B., Engelke, K., & Genant, H. K. (2011) · Bone · doi:10.1016/j.bone.2011.02.005 · Cited by 60
Inhibition of glycogen synthase kinase-3β attenuates glucocorticoid-induced bone loss
Wang, F., Ko, J., Weng, L., Yeh, D., Ke, H.-J., & Wu, S.-L. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.09.009 · Cited by 62
Low Bone Turnover and Low BMD in Down Syndrome: Effect of Intermittent PTH Treatment
Fowler, T. W., McKelvey, K. D., Akel, N. S., Schilden, J. V., Bacon, A. W., Bracey, J. W., Sowder, T., Skinner, R. A., Swain, F. L., Hogue, W. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042967 · Cited by 59
Inhaled Corticosteroids and Bone Health
Chee, C., Sellahewa, L., & Pappachan, J. M. (2015) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401408010085 · Cited by 59
Teriparatide in the treatment of osteoporosis
Stroup, J. S., Kane, M. P., & Abu-Baker, A. M. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070171 · Cited by 55
Ameri, M., Daddona, P. E., & Maa, Y. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9960-9 · Cited by 54
Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions
Bultink, I. E. M., Baden, M., & Lems, W. F. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.761975 · Cited by 56
Jakob, F. J., Oertel, H., Langdahl, B. L., Ljunggren, Ö., Barrett, A., Karras, D., Walsh, J. B., Fahrleitner‐Pammer, A., Rajzbaum, G., Barker, C., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0740 · Cited by 53
Risteli, J., Winter, W. E., Kleerekoper, M., & Risteli, L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00052-4 · Cited by 63
Langdahl, B. L., Ljunggren, Ö., Benhamou, C.-L., Marín, F., Kapetanos, G. A., Kocjan, T., Lespessailles, É., Napoli, N., Nikolic, T., Petto, H., et al. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0143-5 · Cited by 52
Self-citationShen, G., Ren, H. J., Shang, Q., Zhao, W., Zhang, Z., Yu, X., Huang, J., Tang, J., Yang, Z., Liang, D., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33490 · Cited by 52
Advances in treatment of glucocorticoid-induced osteoporosis
Hsu, E., & Nanes, M. S. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000368 · Cited by 56
Mineral and Bone Disorders After Kidney Transplantation
Vangala, C., Pan, J. S.-C., Cotton, R. T., & Ramanathan, V. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00211 · Cited by 64
Updates in CKD-Associated Osteoporosis
Khairallah, P., & Nickolas, T. L. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0491-3 · Cited by 53
Rethinking Bone Disease in Kidney Disease
Damasiewicz, M. J., & Nickolas, T. L. (2018) · JBMR Plus · doi:10.1002/jbm4.10117 · Cited by 65
Glucocorticoid-induced osteoporosis
Silverman, S. L., & Lane, N. E. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0005-4 · Cited by 50
Murphy, D. R., Smolen, L. J., Klein, T. M., & Klein, R. W. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-213 · Cited by 49
Tatsuno, I., Sugiyama, T., Suzuki, S., Yoshida, T., Tanaka, T., Sueishi, M., & Saitō, Y. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1578 · Cited by 54
Sugimoto, R., Watanabe, H., Ikegami, K., Enoki, Y., Imafuku, T., Sakaguchi, Y., Murata, M., Nishida, K., Miyamura, S., Ishima, Y., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.041 · Cited by 49
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
Osteoporosis in chronic obstructive pulmonary disease
Romme, E. A., Smeenk, F. W. J. M., Rutten, E. P. A., & Wouters, E. F. �. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.814402 · Cited by 54
Selective Modification of Bone Quality by PTH, Pamidronate, or Raloxifene
Brennan‐Speranza, T. C., Rizzoli, R., & Ammann, P. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081227 · Cited by 50
Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS
Lyritis, G. P., Marín, F., Barker, C., Pfeifer, M. A., Farrerons, J., Brixen, K., del Pino, J., Keen, R. W., Nickélsen, T., & for the EUROFORS Study Group (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.488516 · Cited by 49
Self-citationGlucocorticoid Excess in Bone and Muscle
Sato, A. Y., Peacock, M., & Bellido, T. (2018) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-018-9242-3 · Cited by 56
Zhang, C., & Song, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.607017 · Cited by 57
Hong, J. M., Teitelbaum, S. L., Kim, T., Ross, F. P., Kim, S., & Kim, H. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.241 · Cited by 48
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 56
Adverse effects of therapy for ANCA-associated vasculitis
Turnbull, J., & Harper, L. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.04.002 · Cited by 48
Bone loss in chronic kidney disease: Quantity or quality?
Zheng, C., Zheng, J.-Q., Wu, C., Lu, C., Shyu, J., Yung-Ho, H., Wu, M., Chiu, I., Wang, Y., Lin, Y., et al. (2016) · Bone · doi:10.1016/j.bone.2016.03.017 · Cited by 55
Iacopo, C., Falchetti, A., Merlotti, D., Cristina, E.-V., & Gennari, L. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1772051 · Cited by 64
Long-term therapy in COPD: any evidence of adverse effect on bone?
Langhammer, A., Forsmo, S., & Syversen, U. (2009) · International Journal of COPD · doi:10.2147/copd.s4797 · Cited by 54
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.